Bio Blast Pharma
Manufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
IsraelPhone Number
(917) 469-1012Website
www.bioblast-pharma.comRevenue
<$5 MillionIndustry
About Bio Blast Pharma
Bio Blast Pharma Org Chart
Director, Preclinical Development
Is Bio Blast Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Bio Blast Pharma has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Bio Blast Pharma had a recent Job posting/layoffs
Product Launch: Get notified when Bio Blast Pharma launches new products
Funding: Get notified immidiatlly once Bio Blast Pharma has new funding data
Check out if Bio Blast Pharma is spiking on competitors!
Bio Blast Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Bio Blast Pharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Bio Blast Pharma
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Bio Blast Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Bio Blast Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Bio Blast Pharma.
Bio Blast Pharma Tech Stack
A closer look at the technologies used by Bio Blast Pharma
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bio Blast Pharma
BioBlast Pharma is a clinical-stage biotechnology company focused on developing therapies for rare and ultra-rare genetic diseases. Founded in 2012 and publicly traded on NASDAQ, the company aims to address unmet medical needs through a diverse portfolio of product candidates. Their therapeutic platforms leverage a deep understanding of disease-cau... Read More